Australian Clinical Labs Ltd (AU:ACL) has released an update.
Australian Clinical Labs Limited (ACL), a leading provider of pathology services, projects its full-year earnings to hit the lower spectrum of its forecast, ranging between $60m to $65m, based on current market trends and unaudited accounts up to April 30, 2024. The company’s financial outlook remains consistent with earlier projections made in February. Investors and stakeholders are keeping a keen eye on ACL’s adherence to its financial guidance amid fluctuating market conditions.
For further insights into AU:ACL stock, check out TipRanks’ Stock Analysis page.
